Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Alirocumab on Postprandial Hyperlipemia in Type 2 Diabetes
NCT03344692Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Feb 2019
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of alirocumab in type 2 diabetes mellitus (T2DM), hyperlipidemia, hypercholesterolemia, dyslipidemia, sponsored by CHU de Nantes. Started Feb 2019; status: completed.
02
Drugs
alirocumab
03
Conditions
type 2 diabetes mellitus (T2DM)hyperlipidemiahypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on NCT03344692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344692.